BZ Bank Aktiengesellschaft has led a CHF35m (€22m) funding round for Pevion Biotech.
BB Biotech Ventures, CC Private Equity Partners and Swiss biochemicals company Bachem Holding also participated in the funding round.
Pevion is developing a range of prophylactic and therapeutic vaccines based on its proprietary virosome technology platform.
Its product pipeline includes vaccines against breast cancer, candida, Rous sarcoma virus, malaria and hepatitis C.
The company was founded in 2002 as a joint venture company with Bachem Holding. Since then it has raised around €35m in venture funding.